Sitagliptin and Pioglitazon effects in the treatment of diabetes

Comparison Efficacy and Safety of Sitagliptin with Pioglitazon in patients with uncontrolled type 2 diabetes on metformin

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015061619554N4

Enrollment

160

Registered

2017-02-07

Start date

2016-04-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus type 2. Insulin-dependent diabetes mellitus ,Non-insulin-dependent diabetes mellitus , Malnutrition-related diabetes mellitus Malnutrition-related diabetes mellitus , Unspecified diabetes mellitus

Interventions

Intervention 1: tablet sitagliptin 50 to 100 mg and tablet metformin 1000 to 2000 mg daily (for3 month). Intervention 2: tablet pioglitazone 15 to 30 mg and tablet metformin 1000 to 2000 mg daily (for

Treatment - Drugs

tablet sitagliptin 50 to 100 mg and tablet metformin 1000 to 2000 mg daily (for3 month)

tablet pioglitazone 15 to 30 mg and tablet metformin 1000 to 2000 mg daily (for 3 month)

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Newly diagnosed type 2 diabetic patients In the past year ; HBA1C between 8 to 9.5; BMI between 35-25; Lack of insulin; written consent to participate in the study criteria ; Exclusion criteria: Liver problems (abnormal level of liver enzymes) (more than 1.5 times the normal); renal failure (BUN and CR abnormal) (creatinine increase greater than1.5); digestive problems (including dyspepsia, diarrhea, vomiting); acidosis (ie, ABG : PH <7/35) heart failure with EF below 35% ; macular edema eye

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
HBA1C. Timepoint: Intervention and three months after intervention. Method of measurement: Elisa.;Fasting blood glucose. Timepoint: Before and three months after intervention. Method of measurement: Elisa.;Bs2hpp. Timepoint: Before and three months after intervention. Method of measurement: Elisa.	—

Secondary

Measure	Time frame
Weight. Timepoint: Intervention and three months after intervention. Method of measurement: Kg using scales.;TG. Timepoint: Before and three months after intervention. Method of measurement: Elisa.;CHOL. Timepoint: Before and three months after intervention. Method of measurement: Elisa.;HDL. Timepoint: Before and three months after intervention. Method of measurement: Elisa.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Jameshorani

Zanjan University of Medical Sciences

ZMDRC@zums.ac.ir+98 24 3377 0814

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026